Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN) Share Price

Price 13,716.00p on 18-11-2026 at 14:04:11
Change -86.00p -0.62%
Buy 13,716.00p
Sell 13,714.00p
Last Trade: Buy 1.00 at 13,716.00p
Day's Volume: 296,283
Last Close: 13,802.00p
Open: 13,770.00p
ISIN: GB0009895292
Day's Range 13,668.00p - 13,850.00p
52wk Range: 11,404.00p - 15,730.00p
Market Capitalisation: £212.72b
VWAP: 13,739.11407p
Shares in Issue: 1.55b

Astrazeneca (AZN) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 1 13,716.00p SI Trade
14:04:11 - 18-Nov-26
Buy* 27 13,716.00p Automatic Execution
14:04:05 - 18-Nov-26
Buy* 73 13,716.00p Automatic Execution
14:04:03 - 18-Nov-26
Buy* 93 13,716.00p Automatic Execution
14:04:03 - 18-Nov-26
Buy* 17 13,716.00p Automatic Execution
14:04:03 - 18-Nov-26
Buy* 71 13,716.00p Automatic Execution
14:04:03 - 18-Nov-26
Buy* 51 13,716.00p Automatic Execution
14:04:03 - 18-Nov-26
Buy* 55 13,716.00p Automatic Execution
14:04:03 - 18-Nov-26
Buy* 27 13,716.00p Automatic Execution
14:04:03 - 18-Nov-26
Buy* 17 13,716.00p Automatic Execution
14:04:03 - 18-Nov-26
See more Astrazeneca trades

Astrazeneca (AZN) Share Price History

Time period:
to
Date Open High Low Close Volume
18th Nov 2026 (Wed) 13,770.00 13,850.00 13,668.00 13,802.00 296,283
17th Nov 2026 (Tue) 13,938.00 13,956.00 13,722.00 13,802.00 1,629,293
16th Nov 2026 (Mon) 14,056.00 14,222.00 13,964.00 14,034.00 2,303,946
13th Nov 2026 (Fri) 13,902.00 14,064.00 13,892.00 13,982.00 1,093,481
12th Nov 2026 (Thu) 14,024.00 14,076.00 13,890.00 13,930.00 2,100,419
11th Nov 2026 (Wed) 13,902.00 13,960.00 13,824.00 13,896.00 1,369,521
10th Nov 2026 (Tue) 14,114.00 14,142.00 13,884.00 13,884.00 3,423,972
9th Nov 2026 (Mon) 13,920.00 14,184.00 13,918.00 14,066.00 2,150,032
6th Nov 2026 (Fri) 13,696.00 13,950.00 13,458.00 13,930.00 2,620,256
5th Nov 2026 (Thu) 14,228.00 14,312.00 13,966.00 14,042.00 5,841,319
4th Nov 2026 (Wed) 13,768.00 14,062.00 13,582.00 14,024.00 3,826,850
3rd Nov 2026 (Tue) 13,964.00 13,984.00 13,760.00 13,760.00 2,536,172
2nd Nov 2026 (Mon) 13,704.00 13,932.00 13,678.00 13,860.00 2,990,997
30th Oct 2026 (Fri) 13,438.00 14,002.00 13,308.00 13,960.00 4,484,899
29th Oct 2026 (Thu) 12,808.00 13,166.00 12,790.00 13,052.00 1,420,886
28th Oct 2026 (Wed) 12,756.00 12,932.00 12,642.00 12,764.00 1,182,356
27th Oct 2026 (Tue) 12,848.00 12,912.00 12,724.00 12,822.00 2,232,121
26th Oct 2026 (Mon) 12,882.00 12,976.00 12,806.00 12,854.00 1,612,470
23rd Oct 2026 (Fri) 12,906.00 12,906.00 12,672.00 12,824.00 2,164,382
22nd Oct 2026 (Thu) 12,602.00 12,980.00 12,526.00 12,980.00 1,798,147
21st Oct 2026 (Wed) 12,602.00 12,688.00 12,536.00 12,614.00 1,768,475
20th Oct 2026 (Tue) 12,440.00 12,626.00 12,388.00 12,618.00 4,421,942
19th Oct 2026 (Mon) 12,440.00 12,468.00 12,298.00 12,400.00 2,087,819
See more Astrazeneca price history

Astrazeneca (AZN) Regulatory News

Date Source Headline
16th Nov 2026 7:15 am RNS Baxfendy recommended for approval in the EU
16th Nov 2026 7:10 am RNS Imfinzi + EV approved in US in bladder cancer
16th Nov 2026 7:05 am RNS Klygefa (gefurulimab) approved in the US
16th Nov 2026 7:00 am RNS Klygefa (gefurulimab) approved in the EU
2nd Nov 2026 3:05 pm RNS Admission of Further Securities to Trading
2nd Nov 2026 3:00 pm RNS Total Voting Rights
30th Oct 2026 7:00 am RNS 3rd Quarter Results
27th Oct 2026 7:30 am RNS Enhertu approved in EU for HER2-positive eBC
26th Oct 2026 2:16 pm RNS Holding(s) in Company
22nd Oct 2026 7:00 am RNS Ultomiris approved in US in IgAN
See more Astrazeneca regulatory news

Astrazeneca (AZN) Share News

AstraZeneca gets US, EU approvals for treatment of autoimmune disorder

16th Nov 2026 09:57

(Alliance News) - AstraZeneca PLC on Monday announced that Alexion's Klygefa treatment received approval in both the US and EU for adults with generalised myasthenia gravis, a rare autoimmune disorder that causes severe muscle weakness. Read More

LONDON BRIEFING: L&G upbeat on earnings; AstraZeneca wins approvals

16th Nov 2026 07:57

(Alliance News) - Legal & General expects full-year earnings growth to exceed its target range following positive third-quarter trading, while Coca-Cola HBC secures approval for a secondary listing in Johannesburg ahead of its Coca-Cola Beverages Africa acquisition. AstraZeneca receives US approval for its Imfinzi bladder cancer treatment and US and EU approvals for Klygefa. Read More

AstraZeneca says Baxfendy recommended for EU approval

13th Nov 2026 12:18

(Alliance News) - AstraZeneca PLC on Friday said the EU's Committee for Medicinal Products for Human Use has recommended Baxfendy, or baxdrostat, for approval as an arterial hypertension treatment. Read More

LONDON BROKER RATINGS: Berenberg raises Autotrader and likes Rightmove

9th Nov 2026 09:00

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday: Read More

LONDON MARKET OPEN: FTSE 100 slumps as global stocks sell off

6th Nov 2026 09:10

(Alliance News) - Stock prices in London opened sharply lower on Friday, with the FTSE 100 falling 1.5% as European markets followed a steep sell-off on Wall Street, while UK house prices recorded their largest annual decline in three years. Read More

See more Astrazeneca news
FTSE 100 Latest
Value10,637.09
Change-52.78

Login to your account

Forgot Password?

Not Registered